Advances in personalized medicine and genomics have led to the development of targeted therapies tailored to individual patients' genetic profiles. Immunotherapies, such as CAR-T cell therapy and checkpoint inhibitors, have shown remarkable success in treating certain types of cancer. Additionally, the use of biomarkers to predict treatment response is improving the selection of suitable drug candidates for clinical trials.
